EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
Zacks
More News
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
Zacks
J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug Tecvayli
JNJ gets a positive CHMP opinion for Tecvayli in combination with Darzalex SC for treating relapsed/refractory multiple myeloma after one prior therapy.
Zacks
ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases
AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.
Zacks
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Zacks
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
Zacks
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
Zacks
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Zacks
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.